HC Wainwright Reiterates “Buy” Rating for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $60.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 90.36% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the company an “overweight” rating in a research report on Friday, March 13th. Piper Sandler restated an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Finally, B. Riley Financial raised their target price on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.09.

Capricor Therapeutics Trading Down 1.2%

CAPR stock opened at $31.52 on Wednesday. Capricor Therapeutics has a 12-month low of $4.30 and a 12-month high of $40.37. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -13.95 and a beta of 0.48. The business’s 50-day moving average is $31.64 and its 200 day moving average is $23.86.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, equities analysts forecast that Capricor Therapeutics will post 0.01 EPS for the current fiscal year.

Insider Activity at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total transaction of $753,250.00. Following the transaction, the chief financial officer directly owned 8,223 shares in the company, valued at $247,758.99. The trade was a 75.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Karimah Es Sabar sold 61,265 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total value of $1,848,365.05. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 172,529 shares of company stock worth $5,302,440. Insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. KBC Group NV acquired a new position in shares of Capricor Therapeutics during the 1st quarter worth approximately $44,000. ACT Capital Management LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $43,000. GoalVest Advisory LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $59,000. Allworth Financial LP boosted its holdings in shares of Capricor Therapeutics by 5,021.5% during the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 3,264 shares during the last quarter. Finally, State of Wyoming boosted its holdings in shares of Capricor Therapeutics by 76.0% during the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 1,913 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.